| Autor: |
Christian, Gege, Eva, Hambruch, Nina, Hambruch, Olaf, Kinzel, Claus, Kremoser |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Handbook of experimental pharmacology. 256 |
| ISSN: |
0171-2004 |
| Popis: |
FXR agonists have demonstrated very promising clinical results in the treatment of liver disorders such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). NASH, in particular, is one of the last uncharted white territories in the pharma landscape, and there is a huge medical need and a large potential pharmaceutical market for a NASH pharmacotherapy. Clinical efficacy superior to most other treatment options was shown by FXR agonists such as obeticholic acid (OCA) as they improved various metabolic features including liver steatosis as well as liver inflammation and fibrosis. But OCA's clinical success comes with some major liabilities such as pruritus, high-density lipoprotein cholesterol (HDL |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
